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Abstract
Quantitative magnetic resonance imaging (MRI) was used to assess global and
regional cerebral volumes in patients with a clinical diagnosis of subcortical
vascular dementia (VD) and Alzheimer’s disease (AD). Whole brain volume,
cerebrospinal fluid volume, volumes of the temporal, frontal and parietal
lobes, the cerebellum and the amygdala-hippocampus complex were deter-
mined using a personal computer-based software. Seventeen patients with
VD, 22 patients with AD and 13 healthy controls were included. Analysis of
covariance using age as covariate demonstrated significant mean differences
between controls and dementia groups with respect to all morphological
parameters. However, apart from the volume of the cerebellum no significant
volumetric differences were found between VD and AD. These results indi-
cate that MRI-based volumetry allows differentiation between AD or VD
from normal controls and that measurement of cerebellar volume may be of
use to separate vascular and degenerative dementia. However, since the distri-
bution of cerebral atrophy in both dementia groups is very similar, it is sug-
gested that the atrophic changes are not specific to the underlying cause but
rather reflect the selective vulnerability of neuronal structures.
OOOOOOOOOOOOOOOOOOOOOO
Introduction
Neurodegenerative disorders and cerebrovascular dis-
ease are the most common causes of dementia in the
elderly population. Epidemiological studies suggest that
Alzheimer’s disease (AD) and vascular dementia (VD)
account for up to 90% of all dementia syndromes [1, 2].
Patients with subcortical lesions of vascular origin result-
ing in progressive dementia and the clinical picture of
‘Binswanger’s disease’ represent an important subgroup
of VD [3]. Although neuroimaging methods such as com-
puterized tomography (CT) and magnetic resonance
imaging (MRI) facilitated the in vivo diagnosis of both
dementia types, clinical differentiation of AD from sub-
cortical VD may still be difficult. Previous neuroimaging
studies regarding the differentiation of VD, AD and nor-
mal aging focused mainly on frequency and type of cere-
bral infarcts and white matter changes [4]. Only few stud-
ies also investigated the diagnostic value of atrophic
changes in the differentiation of the two disorders [5–8].
Those who did, however, were limited since they mainly
used linear and planimetric measurements of ventricular
size or did not restrict their investigations to patients with
subcortical VD.
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Previous studies showed that MRI-based measure-
ment of hippocampal size allows a separation of clinically
diagnosed Alzheimer patients from age-matched nonde-
mented controls with a sensitivity and specificity of 85–
90% [9–15] and may also assist in the differential diagno-
sis of AD from age-associated memory impairment [16]
and depressive pseudodementia [17]. However, the use of
MRI-based volumetry in the differentiation of VD and
AD remains to be established. Neuropathological studies
show that atrophic changes are present in both disorders.
In AD early and extensive pathological changes of the
medial temporal lobe structures are found which only lat-
er spread to involve the temporal and parietal regions and
finally affect nearly all isocortical association areas [18].
In subcortical VD white matter atrophy with progressive
demyelination, neuronal loss and lacunar infarctions is
the main pathomorphological feature leading to enlarged
lateral ventricles, whereas the cortex characteristically ap-
pears intact [3, 19]. Based on these findings, it may be
speculated that in vivo volumetry of the brain and its sub-
structures could establish different patterns of atrophic
changes in the two diseases. In particular, it has been sug-
gested that hippocampal volume reduction may be a char-
acteristic feature of AD and may therefore be useful in the
differential diagnosis [20]. The aims of our study were
accordingly: (1) to establish volumetric differences in the
brain and its substructures between patients with subcor-
tical VD and healthy age-matched controls, and (2) to
compare volumes of brain structures from patients af-
fected with VD with those from AD patients and to deter-
mine differences and/or similarities between these diag-
nostic groups.
Methods
Patients and Control Subjects
The study was approved by a local ethical committee. Patients
were consecutively admitted inpatients under the care of the Section
of Geriatric Psychiatry of the University of Heidelberg and were pro-
spectively included. Patients with a history of head trauma, birth
injury, electroconvulsive therapy and a significant substance abuse
were excluded. All patients underwent thorough standardized gener-
al and neurological examinations as well as a CT scan and laboratory
studies in order to exclude metabolic, toxic and inflammatory causes
of their dementia syndrome. CT scans were carefully screened for the
presence and types of cerebrovascular lesions by an experienced neu-
roradiologist (R.v.K.) who was unaware of the patients’ history and
the results of the clinical examinations. Clinical grouping was based
on the CT scans since MRI scans seem to be more sensitive but less
specific to detect significant cerebral vascular changes. In contrast to
CT studies, in most previous MRI studies white matter changes have
not been correlated with overall cognitive decline. This indicates that
MRI may have a ceiling effect, particularly when T2 weighted scans
are used [4].
An extensive neuropsychological investigation was performed
using a test battery which has been described in detail elsewhere [15].
Severity of cognitive impairment was established on the Mini Mental
State Examination (MMSE) [21] and the Global Deterioration Scale
(GDS) [22].
Diagnosis of VD was strictly based on the criteria of the NINDS-
AIREN work group [23] and a modified Hachinski ischemic score
[24]. Diagnosis of AD followed the criteria given by the NINCDS-
ADRDA work group [25]. The diagnostic procedure used all relevant
information concerning history, clinical, neuropsychological, and
neuroradiological findings. Ambiguous cases in which no consensus
about the diagnosis could be achieved were excluded. The NINDS-
AIREN criteria for VD include the following: (1) presence of demen-
tia, preferably established by clinical examination and documented
by neuropsychological testing; (2) cerebrovascular disease, defined
by the presence of focal signs on neurologic examination and/or evi-
dence of relevant cerebrovascular disease on brain imaging; in case of
Binswanger’s disease this includes multiple basal ganglia and white
matter lacunes or extensive periventricular white matter lesions, or
combinations thereof; (3) a relationship beween the above two disor-
ders, manifested by: (a) onset of dementia within 3 months following
a recognized stroke; (b) abrupt deterioration in cognitive functions;
or fluctuating, stepwise progression of cognitive deficits.
Clinical features which support the diagnosis of VD include:
(a) Early presence of gait disturbance; (b) history of unsteadiness and
frequent falls; (c) early urinary symptoms not explained by a urologic
disease; (d) pseudobulbar palsy, and (e) personality and mood
changes.
The control subjects were volunteers from the local community
and were all in a good mental and physical state of health with no
history of hypertension, diabetes, neurological or psychiatric dis-
eases. In order to exclude any latent brain disorders control subjects
were investigated using the same neuropsychological and clinical
measures. In total, 19 patients with VD, 29 patients with AD and 13
healthy control subjects were investigated. Patients who met the
NINDS-AIREN criteria for VD but showed single or multiple corti-
cal or extensive territorial infarcts were excluded, resulting in a group
of 17 patients who exclusively displayed indications of subcortical
small vessel disease such as extensive white matter lesions, basal gan-
glia and white matter lacunes or a combination of both. The AD
group consisted of 22 patients who were classified as probable AD
and 7 patients who were classified as possible AD according to the
NINCDS-ADRDA criteria. In order to improve homogeneity of the
AD group only the 22 patients with a diagnosis of probable AD were
used for further analysis. In line with the NINDS-ADRDA criteria
none of these 22 patients had evidence of cerebrovascular disease on
CT. This was based on the judgment of the neuroradiologist
(R.v.K.).
MR Image Acquisition and Image Processing
For each patient and control subject two sagittal image data cubes
of the brain were measured: a set of T1-weighted images, providing
differentiation between gray and white matter and a set of T2-
weighted images providing differentiation between tissue and cere-
brospinal fluid. Sagittal images were preferred, because due to ana-
tomical reasons they provide a better volume resolution at a given
slab thickness than transversal images. All measurements were per-
formed on a 1.5-tesla MAGNETOM 63/84 SP Siemens scanner using
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a 3D MPRAGE sequence (TR: 10 ms, TE: 4 ms) for the T1 and a 3D
PSIF sequence (TR: 17 ms, TE: 7 ms) for the T2-weighted image data
cubes. MR images were taken at 15° cranial to the orbitomeatal line.
The total measurement time was about 15 min per patient. Both 3D
image data cubes with a slab thickness of 160 mm consisted of 128
sagittal image slices, resulting in a slice thickness of 1.25 mm. The
slices had an in-plane field of view of 260 mm, the volume pixels
were of the size 1.02 ! 1.02 ! 1.25 mm3.
Image data processing was performed on a conventional 80486/
66 MHz personal computer using the software NMRWin. This soft-
ware provides segmentation and volumetry of MR brain images
based on standard segmentation techniques which allows automatic
quantification of cerebrospinal fluid (CSF) and brain matter com-
partment volumes requiring a minimum of manual interaction.
Detailed structure and function of this software is described else-
where [26].
Whole brain volume, CSF volume and total intracranial volume
were assessed using the semiautomated segmentation function of
NMRWin which segments the brain tissue and CSF slice by slice
making use of both the T1-weighted and the T2-weighted data sets.
The brain tissue compartment included gray and white matter struc-
tures as well as potential lacunes and white matter hyperintensities.
The accuracy of the segmentation process could be controlled visual-
ly on the computer screen. The resulting areas were multiplied with
the slice thickness, summed up and documented in a protocol file.
The whole brain volume included the volume of the hemispheres, the
cerebellum and the upper parts of the brain stem. The total intracra-
nial volume was assessed by adding the whole brain volume and the
CSF volume. The reliability of the method has been demonstrated by
an independent study [27].
The volumes of the amygdala-hippocampus complex, the frontal
lobes, the temporal lobes, the parietal lobes and the cerebellum were
traced manually on 35–40 contiguous slices for each structure using
the manual segmentation function of NMRWin. This requires the
operator to place an exact region of interest (ROI) along the border
lines of the structure to be analyzed, where each ROI has a color
assigned to a specific structure. The measurements were obtained on
the T1-weighted images providing a high gray matter/white matter
contrast and were based on a detailed manual following anatomical
landmarks. The use of a high number of thin slices (1.25 mm) should
minimize partial voluming artifacts and overprojection errors. Mea-
surements were performed 2 times by 2 independent raters who were
unaware of the patients’ diagnosis. In a previously published study a
high test-retest reliability could be demonstrated for all volumetric
measures [15]. Apart from the cerebellum all structures were mea-
sured on coronal slices which were reconstructed from the 3D data-
set. The definitions of boundaries for the amygdala-hippocampus
complex, the temporal and the frontal lobes were described in detail
previously [15]. The boundaries of the parietal lobes were defined as
follows:
The measurement of the parietal lobe started caudally in the coro-
nal slice with the first appearance of the superior parietal gyrus. It
was then continuously measured from caudal to rostral outlining the
cortical surface of the parietal gyri including the superior parietal
gyrus, inferior parietal gyrus, postcentral gyrus, precuneus and the
paracentral gyrus. Subsequently, a straight line was drawn from the
parietooccipital fissure to the intraparietal sulcus in order to separate
the parietal lobe structures from the occipital and the temporal lobe.
With the disappearance of the occipital lobe the subparietal sulcus
served as the starting point of the straight demarcation line. Eventu-
ally, with the first appearance of the occipital horn of the lateral ven-
tricles this line ended in the depth of the parallel sulcus. The mea-
surement of the parietal lobe was terminated as the first slice which
shows the cornu posterior, lateral and anterior of the lateral ventricle
fused was reached.
The measurement of the cerebellum was carried out on about 50
sagittal slices and consisted of outlining the cerebellar surface with
the cursor slice by slice. On the T1-weighted images the cerebellar
boundaries could easily be separated from the adjacent brain struc-
tures and CSF. Pedunculi cerebellares were excluded.
Data Analyses
All computations were performed using the statistical analysis
system [28]. To address potential interindividual differences in head
size, all volumetric data were corrected for the subject’s total intra-
cranial volume. Total intracranial volume seems to be an appropriate
indicator of premorbid brain size, since the brain drives the growth
of the skull during childhood and adolescence. Therefore, we ex-
pected intracranial volume to be approximately the same in patients
and healthy controls. Mathalon et al. [29] demonstrated that this
method can be beneficial in brain imaging measurements because it
improves the correlations with validity criteria, even if this may
result in somewhat less reliable measures.
For statistical analysis we performed in a first step a comparison
of the baseline features (i.e. age, sex, MMSE) between the AD group,
VD group and healthy controls. Since there was a significant age dif-
ference between the VD group and the normal controls an adjust-
ment for age was necessary.
To adjust for effects of age an analysis of covariance with age as a
covariate was performed. An analysis of variance for the age-cor-
rected values with a multiple comparison adjustment (Bonferroni)
for the p values and confidence limits for the differences of least
squares means was applied to test for differences between the patient
groups and the normal control group respectively.
Correlations between the clinical variables and volumetric data
were calculated for each group separately by Spearman rank correla-
tion.
Results
The clinical characteristics of the investigated groups is
shown in table 1. The VD patients were significantly older
than the other groups, gender distribution of the diagnos-
tic groups was similar. 3/17 (17.6%) VD patients but 3/29
(10.3%) AD patients had a history of regular but moder-
ate alcohol consumption. As expected, impairment of cog-
nitive performance of both dementia groups was highly
significant when compared to the controls. However,
severity of dementia did not differ significantly between
VD and AD.
Table 2 shows a comparison between controls, VD,
and AD with respect to the corrected morphometric val-
ues and to the age adjusted values. As expected, the total
intracranial volume did not differ significantly between
the groups.
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Table 1. The clinical characteristics of
the population under investigation Controls VD AD
n 13 17 22
Mean (BSD) age, years 68.23B5.311 76.47B6.621 71.04B8.56
Sex, m/f 3/10 7/10 5/17
Mean (BSD) MMSE 29.33B0.781, 2 18.65B5.851 16.92B6.12
Mean (BSD) duration
of illness, months NA 49.53B66.33 43.32B29.14
Mean (BSD) GDS 1.17B0.391, 2 4.29B0.851 4.12B0.882
Stroke and TIA 0/13 (0) 11/17 (65) 3/22 (9)
Hypertension 3/13 (23) 11/17 (65) 4/22 (18)
Coronary heart disease 3/13 (23) 7/17 (41) 0/22 (0)
Diabetes 1/13 (8) 3/17 (18) 2/22 (9)
Focal signs 0/13 (0) 11/17 (65) 1/22 (4)
Mood disturbances 0/13 (0) 15/17 (88) 13/22 (59)
Gait disturbances/dysarthria 0/13 (0) 12/17 (71) 3/22 (14)
Stepwise progression NA 8/17 (47) 4/22 (18)
Hachinski score [24] (0–10) NA 4.47B1.593 0.41B0.73
Values are absolute (sex) and means with standard deviation. Statistically significant dif-
ferences (p ! 0.05, Duncan’s multiple-range test) are marked with: 1 VD compared to control;
2 AD compared to control; 3 AD compared to VD. NA: Not applicable. Percentages in paren-
theses.
Table 2. Comparison between controls, VD and AD
Controls
(n = 13)
unadjusted adjusted
VD
(n = 17)
unadjusted adjusted
AD
(n = 22)
unadjusted adjusted
Total intracranial
volume, cm3 1,193.4B129.2 1,182.0B121.7 1,239.4B105.5 1,256.0B127.5 1,215.5B123.3 1,209.6B119.8
Whole brain, % 74.1B3.71, 2 73.7B4.11, 2 66.1B4.01 66.7B4.31 65.1B4.22 64.9B4.02
CSF, % 25.9B3.71, 2 26.4B4.31, 2 33.5B4.31 32.5B4.61 34.7B4.52 35.0B4.22
Amygdala-hippocampus
right, % 0.4B0.0531, 2 0.4B0.0611, 2 0.29B0.0571 0.3B0.0641 0.28B0.0642 0.27B0.062
left, % 0.39B0.0561, 2 0.38B0.0511, 2 0.28B0.0471 0.29B0.0541 0.27B0.0482 0.27B0.052
Temporal right, % 4.00B0.521, 2 4.0B0.471, 2 3.05B0.441 3.06B0.51 3.22B0.442 3.22B4.72
Temporal left, % 3.99B0.581, 2 3.95B0.471, 2 3.11B0.431 3.17B0.51 3.25B0.412 3.23B0.472
Frontal right, % 4.41B0.521, 2 4.41B0.451, 2 3.46B0.411 3.46B0.471 3.56B0.472 3.59B0.442
Frontal left, % 4.51B0.621, 2 4.48B0.511, 2 3.49B0.491 3.52B0.531 3.53B0.432 3.55B0.52
Parietal right, % 5.13B0.551, 2 5.17B0.521, 2 3.92B0.491 3.87B0.531 3.82B0.462 3.83B0.492
Parietal left, % 5.23B0.521, 2 5.27B4.91, 2 4.02B0.481 3.98B0.51 3.96B0.422 3.97B4.72
Cerebellum, % 10.38B0.751, 2 10.4B0.791, 2 8.00B0.841, 3 8.00B0.811 9.26B0.662, 3 9.26B0.762, 3
Values are given as percentage of the total intracranial volume and cm3 (total intracranial volume) respectively. Values are means and
standard deviation. The unadjusted values and the age-adjusted values are listed. Statistical significant differences (p ! 0.05, analysis of
variance with age as the covariate and with Bonferroni correction) are marked with: 1 VD compared to control; 2 AD compared to control;
3 AD compared to VD.
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Fig. 1. Corrected and age-adjusted val-
ues for the cerebellar volume in patients with
AD, subcortical VD and controls. All three
groups show significantly different distribu-
tions (p ! 0.05). Means and standard devia-
tions are given in table 2.
After correction for total intracranial volume, both
dementia groups demonstrated significantly lower vol-
umes than controls with respect to all volumetric parame-
ters. The greatest mean difference was observed for the
volume of the amygdala-hippocampus complex bilater-
ally. Only the volume of the cerebellum differentiated
between AD and VD and was significantly smaller in the
latter group (see also fig. 1). However, no significant dif-
ferences were found between VD and AD with respect to
the whole brain volume, the amygdala-hippocampus
complex and the frontal, temporal, and parietal lobes.
Within both dementia groups no significant correlations
were found between the volumetric data age and duration
of the disease (Spearman rank correlation).
Discussion
The results of our study indicate that: (1) subcortical
VD is associated with a significant global and regional
decrease in cerebral and cerebellar volume which can be
quantified by MRI-based volumetry; (2) mildly to moder-
ately impaired patients with subcortical VD and patients
with AD show a similar distribution of cerebral volume
reduction including a marked volume loss of the medial
temporal lobe structures, and (3) volume of the cerebel-
lum is significantly smaller in patients with VD when
compared to patients with AD.
Previously, MRI-based volumetry was used by several
investigators to quantify cerebral atrophy in patients with
AD [9–15]. Most of these studies revealed a significant
volume reduction of the entire brain and its substructures
when groups of AD patients were compared with age-
matched healthy controls. The results of our study show
that significant global and regional volume loss also
occurs in patients with a clinical diagnosis of subcortical
VD. This confirms and extends several findings derived
from CT studies which suggested that cerebral atrophy is
a common finding in VD. Pullicino et al. [30] reported a
frequency of 83% of atrophy in a group of patients with
VD. In the series of Erkinjuntti et al. [5] 88% of patients
with a moderate VD but all patients with a severe VD
showed indications of cortical atrophy. Based on MRI
findings, Schmidt [8] reported a frequency of 58.1% of
moderate to severe cortical atrophy and 80.7% of moder-
ate to severe ventricular enlargement in a group of 31
patients with VD. However, all these studies used either
visual rating or linear measurement of atrophy. Our study
for the first time uses MRI-based volumetry in order to
quantify these changes.
Vascular dementia is a heterogeneous syndrome which
can be associated with different cerebrovascular lesions
including multiple large vessel infarcts, strategic single
infarcts, small vessel disease with single or multiple lacu-
nar lesions, and diffuse white matter lesions. It is there-
fore conceivable that a cerebral volume deficit in VD may
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be caused mainly or solely by the cerebral substance loss
induced by single or multiple large territorial infarcts. In
order to address this problem we restricted our investiga-
tions to patients suffering from the subcortical or Bins-
wanger’s type of VD. Accordingly, the volume loss in our
VD patients may reflect the diffuse process of white mat-
ter atrophy which has been described pathologically in
this patient group. Previous MRI studies showed that
nondemented and demented patients with cerebrovascu-
lar disease differed with respect to the prevalence of dif-
fuse cerebral volume loss insofar as the presence of cere-
bral atrophy in a patient with cerebrovascular disease
increased the likelihood that this patient belonged to the
demented group [31, 32]. Our findings support the view
of Liu et al. [32] who concluded from their data that the
global brain tissue loss in VD is one of the most important
factors leading to the severe cognitive deficits.
According to our data no global or regional measure of
cerebral volume differentiated significantly between AD
and subcortical VD. These results are in agreement with
the findings of previous studies [5, 6, 8] who failed to
demonstrate significant differences between VD and AD
when using measures of cortical and central cerebral atro-
phy. Our findings are of particular interest with regard to
the specificity of the medial temporal volume reduction
in the differential diagnosis of AD which yet has not been
fully established. For at least two reasons, it has been
argued that medial temporal lobe atrophy may be an early
and specific marker in the diagnosis of AD. Firstly, the
medial temporal lobe appears to be the area of the greatest
and probably the earliest pathological changes in AD [18,
33]. Secondly, a hippocampal-type amnesia is an early
and prominent clinical feature of AD which has led some
authors to refer to AD as being mainly a ‘hippocampal
dementia’ [34, 35]. Indeed, several MRI-based volumet-
ric studies revealed early and severe medial temporal lobe
atrophy in AD patients and demonstrated a sensitivity
and specificity of 85–90% in separating clinically diag-
nosed patients from age-matched nondemented controls
[36]. In view of our data, AD patients tended to have a
greater mean volume reduction of the amygdala-hippo-
campus complex when compared to VD (F33% in AD
vs. F27% in VD). However, these differences were not
significant and considerable volume reduction of the
amygdala-hippocampus complex also occurred in VD.
These findings are supported by the recent results of
Laakso et al. [37] who compared hippocampal volumes in
AD, Parkinson’s disease with and without dementia, VD,
and healthy controls. In this MRI study, a significant vol-
ume reduction of the hippocampus was not only observed
in AD patients but also in the other patient groups. This is
further confirmed by the results of Frisoni et al. [38], who
performed linear measurements of medial temporal lobe
structures in patients with frontotemporal dementia in
comparison to AD patients and found that the measure of
hippocampal atrophy was the least specific in the differ-
entiation of the two dementia syndromes, showing as
much atrophy in frontotemporal dementia as in AD.
Ohnishi et al. [39] conducted a SPECT study and found
that hippocampal hypoperfusion was observed in de-
mented patients regardless of etiology including AD, VD
and dementia with motor neuron disease. On the basis of
these and our findings, hippocampal volume reduction is
probably not a specific phenomenon of AD, but also
occurs in other types of dementia such as VD. Our in vivo
results correspond to recent postmortem findings in pa-
tients with VD showing that hippocampal volume reduc-
tion is also present in patients with dementia of pure vas-
cular origin [40, 41]. Olsson et al. [41] stated that vascular
factors seem to be of pathogenetic significance for the
appearance of hippocampal sclerosis at least in some cases
of senile dementia. In the adult human brain, acute hyp-
oxic episodes result in a certain pattern of nerve cell dam-
age from which a hierarchy of neuronal vulnerability can
be formed [42]. Among the most sensitive regions are the
phylogenetically ‘older’ brain structures like the hippo-
campal formation including the neurons of the Sommer
sector (CA1) and the end folium (CA 3–4) which are par-
ticularly sensitive. Subsequent to nerve cell damage in
VD there is in these regions of the hippocampus activa-
tion of glial cells and finally gliosis. Thus, hippocampal
volume reduction in VD and AD are probably caused by a
different pathological mechanism. This points toward the
selective vulnerability of several neuroanatomical struc-
tures which may be independent of the nature of a partic-
ular noxious agent. Animal experiments support the hy-
pothesis that chronic cerebrovascular insufficiency and
acute hypoxia can result in a pattern of brain damage that
shows many parallels to Alzheimer type changes [43, 44].
The hippocampal volume reduction observed in our VD
patients could be explained on the basis of these experi-
mental findings.
According to our results, patients with VD are charac-
terized by a significantly greater cerebellar volume reduc-
tion when compared to patients with AD. Our findings
may be explained by the observation that lacunar cerebel-
lar infarcts occur regularly in Binswanger’s disease [3] and
multi-infarct dementia [45]. In a CT study of Barclay and
Brady [45], cerebellar atrophy was absent in AD but a
common finding in patients with a mixed AD and VD
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pathology. Chan et al. [46] reported recently that MRI-
derived multifocal hypointense lesions in the cerebellum
were associated with the diagnosis of chronic hyperten-
sion which is believed to be the most important risk factor
for the development of VD. This is further supported by
the results of positron emission tomography studies which
indicate that cerebellar glucose metabolism is reduced in
patients with stroke [47] and VD [48] but not in normal
aging and patients with pure AD. However, neuropatho-
logical investigations show that AD pathology does not
spare the cerebellum [49] and our own results suggest that
cerebellar volume reduction can also be found in AD.
Thus, cerebellar volume reduction shows a great overlap
when VD and AD patients are compared and may hence
only be of limited use in the differential diagnosis of the
two dementia syndromes.
The main limitation of our study is the fact that the
diagnostic classification of the dementia type was based
solely on clinical and neuroradiological information. Al-
though the diagnosis was strictly based on internationally
accepted criteria, there is still some uncertainty concern-
ing the reliability of the standardized diagnostic tools [50.
51]. It may well be that some of our patients have been
misclassified or that our patient groups are heteroge-
neous, possibly owing to a certain proportion of patients
with so-called ‘mixed dementia’. There is growing evi-
dence from the literature that coexisting vascular patholo-
gy in AD is far more common than previously acknowl-
edged [52]. Conversely, it may be argued that satisfaction
of the NINDS-AIREN criteria can not be taken as a suffi-
cient proof that ischemic mechanisms are the exclusive
explanation for an individual patient’s dementia. Our
failure to find significant differences between VD and AD
may therefore reflect insufficient selectivity of the in vivo
applicable diagnostic criteria resulting in an inhomogene-
ity of the diagnostic groups. However, a recent clinicopa-
thological correlation study showed that the use of the
NINDS-AIREN criteria led to 0.80 specificity with re-
spect to the diagnosis of VD when the neuropathological
diagnosis was used as a gold standard and by the applica-
tion of these criteria 91% of patients with Alzheimer’s dis-
ease could be successfully excluded [53]. Nonetheless, it
will be necessary to carefully follow-up our patients in
order to confirm the clinical diagnosis.
Taking into account the above-mentioned limitation,
we conclude that although MRI-based volumetry is suffi-
ciently sensitive to detect atrophic changes in dementia
patients, it may only be of limited use in the differentia-
tion between clinically diagnosed patients with AD and
subcortical VD. The pattern of volume reduction does not
seem to be specific to the underlying cause but rather
reflects the selective vulnerability of neuronal structures.
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